Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,018 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical and biomarker factors affecting survival in patients with platinum-sensitive relapsed ovarian cancer receiving olaparib monotherapy: a multicenter retrospective study.
Tashiro R, Kawazoe H, Mamishin K, Seto K, Udagawa R, Saito Y, Hashimoto H, Shimoi T, Yonemori K, Yonemura M, Terakado H, Nishimura T, Kawasaki T, Furukawa T, Nakamura T. Tashiro R, et al. Among authors: hashimoto h. Sci Rep. 2023 Jul 24;13(1):11962. doi: 10.1038/s41598-023-39224-0. Sci Rep. 2023. PMID: 37488223 Free PMC article.
Randomized controlled study comparing two doses of intravenous granisetron (1 and 3 mg) for acute chemotherapy-induced nausea and vomiting in cancer patients: a non-inferiority trial.
Yonemura M, Katsumata N, Hashimoto H, Satake S, Kaneko M, Kobayashi Y, Takashima A, Kato Y, Takeuchi M, Fujiwara Y, Yamamoto H, Hojo T. Yonemura M, et al. Among authors: hashimoto h. Jpn J Clin Oncol. 2009 Jul;39(7):443-8. doi: 10.1093/jjco/hyp036. Epub 2009 Apr 24. Jpn J Clin Oncol. 2009. PMID: 19395466 Clinical Trial.
A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy.
Yanai T, Iwasa S, Hashimoto H, Ohyanagi F, Takiguchi T, Takeda K, Nakao M, Sakai H, Nakayama T, Minato K, Arai T, Suzuki K, Shimada Y, Nagashima K, Terakado H, Yamamoto N. Yanai T, et al. Among authors: hashimoto h. Int J Clin Oncol. 2018 Apr;23(2):382-388. doi: 10.1007/s10147-017-1200-4. Epub 2017 Oct 16. Int J Clin Oncol. 2018. PMID: 29039073 Clinical Trial.
Tolerability and Efficacy of Neoadjuvant Chemotherapy with a Tri-Weekly Interval Methotrexate, Doxorubicin, Vinblastine, and Cisplatin Regimen for Patients with Locally Advanced Bladder Cancer.
Arai S, Hara T, Matsui Y, Koido K, Hashimoto H, Shinoda Y, Komiyama M, Fujimoto H, Terakado H. Arai S, et al. Among authors: hashimoto h. Case Rep Oncol. 2018 Jul 5;11(2):450-460. doi: 10.1159/000490458. eCollection 2018 May-Aug. Case Rep Oncol. 2018. PMID: 30079018 Free PMC article.
Evaluation of aprepitant and fosaprepitant in pediatric patients.
Saito Y, Kumamoto T, Arima T, Shirakawa N, Ishimaru S, Sonoda T, Nakajima M, Sugiyama M, Arakawa A, Hashimoto H, Makino Y, Ogawa C, Yamaguchi M. Saito Y, et al. Among authors: hashimoto h. Pediatr Int. 2019 Mar;61(3):235-239. doi: 10.1111/ped.13780. Epub 2019 Mar 5. Pediatr Int. 2019. PMID: 30615239
Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: a multicenter retrospective study.
Egami S, Kawazoe H, Hashimoto H, Uozumi R, Arami T, Sakiyama N, Ohe Y, Nakada H, Aomori T, Ikemura S, Fukunaga K, Yamaguchi M, Nakamura T. Egami S, et al. Among authors: hashimoto h. J Cancer. 2021 Feb 16;12(7):2105-2112. doi: 10.7150/jca.53242. eCollection 2021. J Cancer. 2021. PMID: 33754009 Free PMC article.
4,018 results